NPI 1154001675: Open Payments
NPI 1154001675. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$196 in 12 payments from 8 companies in 2025. Trend: 2023 $119 · 2024 $498 · 2025 $196
Food & beverage: $196
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $45 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $37 |
| Exact Sciences Corporation | 2 | $35 |
| ABBVIE INC. | 1 | $20 |
| Dexcom, Inc. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Amgen Inc. | 1 | $14 |
Products named: Kerendia, Ozempic, VRAYLAR, Cologuard Collection Kit, Dexcom G6 Transmitter, The Cologuard Plus Collection Kit, XIFAXAN, Rybelsus.
